Search
EDP1815
go.drugbank.com/drugs/DB16486InvestigationalEDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal beha...
STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Mupadolimab
go.drugbank.com/drugs/DB16488InvestigationalCPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). ...
RESP301
go.drugbank.com/drugs/DB16497InvestigationalIt was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary
BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...
HLX70
go.drugbank.com/drugs/DB16509InvestigationalHLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics
MPT0B640
go.drugbank.com/drugs/DB16512InvestigationalMPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.